Tyligand Bioscience Presents Preclinical Data on FDA IND-Cleared KRAS G12D Inhibitor TSN1611 at the 2024 AACR Annual Meeting

<div id="sp-page-builder" class="sp-page-builder sppb-article-page-wrapper"><div class="page-content"><section id="section-id-1676542178169" class="sppb-section" ><div class="sppb-row-container"><div class="sppb-row"><div class="sppb-col-md-12" id="column-wrap-id-1676542178168"><div id="column-id-1676542178168" class="sppb-column" ><div class="sppb-column-addons"><div id="sppb-addon-wrapper-1676542178172" class="sppb-addon-wrapper"><div id="sppb-addon-1676542178172" class="clearfix " ><div class="sppb-addon sppb-addon-text-block "><div class="sppb-addon-content"><p><span style="font-size: 14pt;">April 5, 2024 – Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapies for drug-resistant tumors, presented the preclinical research results of its independently developed KRAS G12D inhibitor TSN1611 (Poster #3315) at the American Association for Cancer Research (AACR) Annual Meeting. </span> <p><span style="font-size: 14pt;">TSN1611 is a highly potent and selective small molecule drug independently developed by Tyligand Bioscience targeting tumors harboring the KRAS G12D mutation, a key driver in the progression of various malignancies. The oral formulation of TSN1611 has been cleared by the U.S. Food and Drug Administration (FDA) for clinical trials, marking a significant step in the development of this potential therapy. </span> <p><span style="font-size: 14pt;">"Preclinical studies indicate that TSN1611 has the potential to improve the current treatment landscape for patients with KRAS G12D-mutant tumors. We are excited to share our findings with the scientific and medical communities," said <strong>Dr. Tony Zhang, Chief Executive Officer of Tyligand Bioscience</strong>. "We are committed to advancing the development of this drug with full speed and high quality, with the hope of benefiting cancer patients worldwide as early as possible." </span> <p><span style="font-size: 14pt;">KRAS mutations are among the most common oncogenic mutations, and targeting the most prevalent G12D mutation remains highly challenging. Despite significant advances in cancer research and treatment in recent years, KRAS-driven tumors continue to present a substantial unmet medical need, highlighting the urgency for innovative therapeutic options. </span> <p><span style="font-size: 14pt;">The data presented at the 2024 AACR Annual Meeting demonstrates TSN1611's favorable druggability in inhibiting the KRAS G12D target, as well as its in vivo efficacy and safety in animal models. The FDA IND clearance represents a crucial step forward in the clinical evaluation of its safety and efficacy.</span> <div id="sppb-addon-wrapper-1676542637512" class="sppb-addon-wrapper"><div id="sppb-addon-1676542637512" class="clearfix " ><div class="sppb-addon sppb-addon-raw-html "><div class="sppb-addon-content"><blockquote class="block-quote"> <p> Tyligand Bioscience is a clinical-stage biotech company founded in 2017, focusing on the discovery and development of innovative cancer therapeutics. The company commenced business operations in 2018. Leveraging decades of profound experience in leading drug discovery and development at multinational pharmaceutical companies, the management team has successfully established technology platforms with fully integrated capabilities across small molecules and antibody-drug conjugates (ADCs). Serving as an innovation engine, these platforms have enabled the company to build a diversified pipeline encompassing multiple drug candidates. <p> Consistently driven by the mission to address significant unmet clinical needs, Tyligand Bioscience is dedicated to becoming a leading global biopharmaceutical enterprise. By continuously delivering high-quality, differentiated innovative therapies, the company aims to improve the quality of life for patients worldwide and create long-term commercial value. <p>For more info about Tyligand Bioscience, please visit <A href="https://en.tyligand.com.cn/">www.tyligand.com</A> <span><strong class="text-secondary-color">- Tyligand Bioscience </strong></span> </blockquote> <nav class="pagenavigation" aria-label="Page Navigation"> <span class="pagination ms-0"> <a class="btn btn-sm btn-secondary previous" href="/tyligand-news/news-release/tyligand-tsn1611-fpi-fpd-first-patient-dosed-selective-orally-bioavailable-kras-g12d-inhibitor" rel="prev"> <span class="visually-hidden"> Previous article: Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor </span> <span class="icon-chevron-left" aria-hidden="true"></span> <span aria-hidden="true">Prev</span> </a> <a class="btn btn-sm btn-secondary next" href="/tyligand-news/news-release/tyligand-first-patient-dosed-p1-tsn222-datia" rel="next"> <span class="visually-hidden"> Next article: Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN222，the Global First Dual Action Tumor Immune Agonist </span> <span aria-hidden="true">Next</span> <span class="icon-chevron-right" aria-hidden="true"></span> </a> </span> </nav>

The release as fetched from its publisher. tyligand.com.cn ↗